A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Inclusion Criteria:

• Diagnosis of plaque psoriasis (PsO) for ≥ 6 months

• Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)

• Deemed by Investigator to be eligible for phototherapy or systemic therapy

• Psoriatic plaques must cover ≥ 10% of body surface area at baseline

• Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician GlobalAssessment (sPGA) ≥ 3 at baseline

Exclusion Criteria:

• Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)

• Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediatedconditions that are commonly associated with PsO for which a participant requirescurrent systemic immunosuppressant medical treatment

• Any significant acute or chronic medical illness

Other protocol-defined inclusion/exclusion criteria apply